ABEONA THERAPEUTICS INC. Operating Lease, Right-of-Use Asset, Amortization Expense
ABEONA THERAPEUTICS INC. (ABEO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $347.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $168.00K, a 25.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $179.00K, a 36.30% decline year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $229.00K, a 3.38% decline year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $280.00K, a 19.15% increase year-over-year.
- ABEONA THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.01M, a 12.29% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $903.00K, a 0.77% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $910.00K, a 38.68% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.48M, a 22.24% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $347.00K 10-Q · filed 2026-08-13 | $576.00K derived: sum of 3 quarters · filed 2026-08-13 | $856.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $179.00K 10-Q · filed 2026-05-13 | $408.00K derived: sum of 2 quarters · filed 2026-05-13 | $688.00K derived: sum of 3 quarters · filed 2026-05-13 | $912.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $509.00K derived: sum of 2 quarters · filed 2026-03-17 | $733.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.01M 10-K · filed 2026-03-17 |
| 2025-09-30 | $280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $504.00K derived: sum of 2 quarters · filed 2026-08-13 | $785.00K 10-Q · filed 2025-11-12 | $1.02M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $224.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $505.00K 10-Q · filed 2026-08-13 | $742.00K derived: sum of 3 quarters · filed 2026-08-13 | $977.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $281.00K 10-Q · filed 2026-05-13 | $518.00K derived: sum of 2 quarters · filed 2026-05-13 | $753.00K derived: sum of 3 quarters · filed 2026-05-13 | $951.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $472.00K derived: sum of 2 quarters · filed 2026-03-17 | $670.00K derived: sum of 3 quarters · filed 2026-03-17 | $903.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $433.00K derived: sum of 2 quarters · filed 2025-11-12 | $666.00K 10-Q · filed 2025-11-12 | $896.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $198.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $431.00K 10-Q · filed 2025-08-14 | $661.00K derived: sum of 3 quarters · filed 2025-08-14 | $891.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $233.00K 10-Q · filed 2025-05-15 | $463.00K derived: sum of 2 quarters · filed 2025-05-15 | $693.00K derived: sum of 3 quarters · filed 2025-05-15 | $916.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $460.00K derived: sum of 2 quarters · filed 2025-03-20 | $683.00K derived: sum of 3 quarters · filed 2025-03-20 | $910.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $453.00K derived: sum of 2 quarters · filed 2024-11-14 | $680.00K 10-Q · filed 2024-11-14 | $960.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $223.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $450.00K 10-Q · filed 2024-08-12 | $730.00K derived: sum of 3 quarters · filed 2024-08-12 | $1.03M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $227.00K 10-Q · filed 2024-05-15 | $507.00K derived: sum of 2 quarters · filed 2024-05-15 | $812.00K derived: sum of 3 quarters · filed 2024-05-15 | $1.41M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $280.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $585.00K derived: sum of 2 quarters · filed 2024-03-18 | $1.18M derived: sum of 3 quarters · filed 2024-03-18 | $1.48M 10-K · filed 2024-03-18 |
| 2022-09-30 | $305.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $902.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.20M 10-Q · filed 2023-11-13 | $1.59M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $899.00K 10-Q · filed 2023-08-08 | $1.29M derived: sum of 3 quarters · filed 2023-08-08 | $1.57M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $302.00K 10-Q · filed 2023-05-11 | $691.00K derived: sum of 2 quarters · filed 2023-05-11 | $973.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.25M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $389.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $671.00K derived: sum of 2 quarters · filed 2023-03-29 | $946.00K derived: sum of 3 quarters · filed 2023-03-29 | $1.21M 10-K · filed 2023-03-29 |
| 2021-09-30 | $282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $557.00K derived: sum of 2 quarters · filed 2022-11-14 | $825.00K 10-Q · filed 2022-11-14 | $1.09M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $543.00K 10-Q · filed 2022-08-11 | $806.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.06M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $268.00K 10-Q · filed 2022-05-13 | $531.00K derived: sum of 2 quarters · filed 2022-05-13 | $787.00K derived: sum of 3 quarters · filed 2022-05-13 | $1.04M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $519.00K derived: sum of 2 quarters · filed 2022-03-31 | $770.00K derived: sum of 3 quarters · filed 2022-03-31 | $1.01M 10-K · filed 2022-03-31 |
| 2020-09-30 | $256.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $507.00K derived: sum of 2 quarters · filed 2021-11-15 | $752.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $496.00K 10-Q · filed 2021-07-28 | ||
| 2020-03-31 | $245.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |